BriaCell Quadruples Progression Free Survival (PFS) in Patient With "Eye-Bulging" Metastatic Breast Cancer
Canada Net Change Percentage Gainers & Losers
10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
BriaCell Presents Clinical Efficacy Data at ASCO 2024
Express News | Briacell Initiates Patient Enrollment in First-in-Human Study of Bria-Ots™ in Advanced Metastatic Breast Cancer
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer
Express News | BriaCell Therapeutics Announces Clinical Supply Agreement With BeiGene To Evaluate Safety And Efficacy Of Bria-OTS, BriaCell's Next Generation Immunotherapy
Express News | Briacell Announces Clinical Supply Agreement With Beigene for Bria-Ots™ First in Human Study
BriaCell Announces Clinical Supply Agreement With BeiGene for Bria-OTS First in Human Study
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
BriaCell Therapeutics Analyst Ratings
This BriaCell Therapeutics Insider Increased Their Holding By 55% Last Year
H.C. Wainwright Maintains BriaCell Therapeutics(BCTX.US) With Buy Rating, Maintains Target Price $18
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing
BriaCell Therapeutics Secures $5M in Funding
Express News | Briacell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Express News | BriaCell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $5 Million Registered Direct Offering of 2,402,935 Shares and Warrants at a Combined Purchase Price of $2 per Share
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble